Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia (PIT) is a rare blood disorder where the immune system mistakenly attacks and destroys platelets, leading to a low platelet count and increased risk of bleeding and bruising.
Primary Immune Thrombocytopenia: Belantamab Mafodotin Study
We are investigating a new treatment for adults with primary immune thrombocytopenia who have previously received other therapies. The study aims to assess the safety and effectiveness of this new drug.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Do you have a platelet count of less than 30,000 cells per microliter?
- Have you had treatment with corticosteroids for your condition before?
- Are you currently pregnant or breastfeeding?
- Have you had major surgery in the past 4 weeks?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Belantamab mafodotin
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Alexandra Hospital
Plasma cell dyscrasias unit/Department of clinical therapeutics Alexandra Hospital
Athens, Greece
University General Hospital Of Thessaloniki Ahepa
1st Propedeutic Department of Internal Medicine, University General Hospital of Thessaloniki Ahepa
Sykiés, Greece
Sponsor: Hellenic Society Of Hematology
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.